Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gastric Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 132 articles:
HTML format
Text format



Single Articles


    May 2018
  1. WANG G, Zhao J, Song Y, Zhang W, et al
    Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer.
    BMC Cancer. 2018;18:547.
    PubMed     Text format     Abstract available


  2. HSIEH YY, Tung SY, Pan HY, Yen CW, et al
    Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients.
    BMC Cancer. 2018;18:508.
    PubMed     Text format     Abstract available


  3. HUANG Z, Liu Y, Yang C, Li X, et al
    Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer.
    BMC Cancer. 2018;18:515.
    PubMed     Text format     Abstract available


  4. HONG SA, Yoo SH, Lee HH, Sun S, et al
    Prognostic value of Dickkopf-1 and ss-catenin expression in advanced gastric cancer.
    BMC Cancer. 2018;18:506.
    PubMed     Text format     Abstract available


    April 2018
  5. WANG T, Lu ZY, Tu XF, Zhang SH, et al
    Computerized tomography findings in calcified signet-ring gastric cancer receiving chemotherapy: a case report.
    BMC Cancer. 2018;18:474.
    PubMed     Text format     Abstract available


  6. LINK H, Angele M, Schuller M, Ganschow P, et al
    Extra-capsular growth of lymph node metastasis correlates with poor prognosis and high SOX9 expression in gastric cancer.
    BMC Cancer. 2018;18:483.
    PubMed     Text format     Abstract available


  7. ZHANG C, Li Z, Xu L, Che X, et al
    CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
    BMC Cancer. 2018;18:462.
    PubMed     Text format     Abstract available


  8. ITO S, Ohashi Y, Sasako M
    Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    BMC Cancer. 2018;18:449.
    PubMed     Text format     Abstract available


  9. BRENKMAN HJF, Gertsen EC, Vegt E, van Hillegersberg R, et al
    Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study).
    BMC Cancer. 2018;18:450.
    PubMed     Text format     Abstract available


  10. LIU HN, Wu H, Tseng YJ, Chen YJ, et al
    Serum microRNA signatures and metabolomics have high diagnostic value in gastric cancer.
    BMC Cancer. 2018;18:415.
    PubMed     Text format     Abstract available


  11. GIRARDI DM, de Lima MA, Pereira GCB, Negrao MV, et al
    Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis.
    BMC Cancer. 2018;18:378.
    PubMed     Text format     Abstract available


    March 2018
  12. SUNDAR R, Rha SY, Yamaue H, Katsuda M, et al
    A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.
    BMC Cancer. 2018;18:332.
    PubMed     Text format     Abstract available


  13. ZHANG N, Chai D, Du H, Li K, et al
    Expression of Reg IV and SOX9 and their correlation in human gastric cancer.
    BMC Cancer. 2018;18:344.
    PubMed     Text format     Abstract available


  14. MULLER V, Clemens M, Jassem J, Al-Sakaff N, et al
    Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    BMC Cancer. 2018;18:295.
    PubMed     Text format     Abstract available


  15. HIRAHARA N, Tajima Y, Fujii Y, Kaji S, et al
    Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis.
    BMC Cancer. 2018;18:285.
    PubMed     Text format     Abstract available


    February 2018
  16. LEE YH, Lee JW, Jang HS
    Correction to: Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer.
    BMC Cancer. 2018;18:232.
    PubMed     Text format     Abstract available


  17. JIAO XD, Ding C, Zang YS, Yu G, et al
    Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
    BMC Cancer. 2018;18:206.
    PubMed     Text format     Abstract available


  18. NAMIKAWA T, Maeda H, Kitagawa H, Oba K, et al
    Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
    BMC Cancer. 2018;18:186.
    PubMed     Text format     Abstract available


  19. AHN MJ, Lee K, Lee KH, Kim JW, et al
    Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report.
    BMC Cancer. 2018;18:173.
    PubMed     Text format     Abstract available


  20. FENG F, Zheng G, Guo X, Liu Z, et al
    Impact of body mass index on surgical outcomes of gastric cancer.
    BMC Cancer. 2018;18:151.
    PubMed     Text format     Abstract available


  21. KIM SH, Yoo HS, Joo MK, Kim T, et al
    Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
    BMC Cancer. 2018;18:150.
    PubMed     Text format     Abstract available


  22. MARIETTE C, Renaud F, Piessen G, Gele P, et al
    The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers.
    BMC Cancer. 2018;18:139.
    PubMed     Text format     Abstract available


  23. BRAGA-NETO MB, Carneiro JG, de Castro Barbosa AM, Silva IS, et al
    Clinical characteristics of distal gastric cancer in young adults from Northeastern Brazil.
    BMC Cancer. 2018;18:131.
    PubMed     Text format     Abstract available


    January 2018
  24. MIAO ZF, Liu XY, Wang ZN, Zhao TT, et al
    Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis.
    BMC Cancer. 2018;18:118.
    PubMed     Text format     Abstract available


  25. MATSUMOTO H, Kawazoe A, Shimada K, Fukuoka S, et al
    A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
    BMC Cancer. 2018;18:120.
    PubMed     Text format     Abstract available


  26. NISHIBEPPU K, Komatsu S, Ichikawa D, Imamura T, et al
    Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
    BMC Cancer. 2018;18:108.
    PubMed     Text format     Abstract available


  27. CAO QH, Liu F, Li CZ, Liu N, et al
    Testes-specific protease 50 (TSP50) promotes invasion and metastasis by inducing EMT in gastric cancer.
    BMC Cancer. 2018;18:94.
    PubMed     Text format     Abstract available


  28. MACALINDONG SS, Kim KH, Nam BH, Ryu KW, et al
    Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center.
    BMC Cancer. 2018;18:73.
    PubMed     Text format     Abstract available


  29. LI Z, Li Z, Zhang L, Liu Q, et al
    Staging laparoscopy for locally advanced gastric cancer in Chinese patients: a multicenter prospective registry study.
    BMC Cancer. 2018;18:63.
    PubMed     Text format     Abstract available


  30. SAEKI H, Emi Y, Oki E, Tokunaga S, et al
    Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
    BMC Cancer. 2018;18:57.
    PubMed     Text format     Abstract available


  31. ZENG B, Shi W, Tan G
    MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway.
    BMC Cancer. 2018;18:34.
    PubMed     Text format     Abstract available


    December 2017
  32. HUANG J, He Y, Mcleod HL, Xie Y, et al
    miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ beta-catenin/EMT signaling cascade in gastric cancer.
    BMC Cancer. 2017;17:886.
    PubMed     Text format     Abstract available


  33. LU Y, Xu Q, Zuo Y, Liu L, et al
    Isoprenaline/beta2-AR activates Plexin-A1/VEGFR2 signals via VEGF secretion in gastric cancer cells to promote tumor angiogenesis.
    BMC Cancer. 2017;17:875.
    PubMed     Text format     Abstract available


  34. KELLER S, Kneissl J, Grabher-Meier V, Heindl S, et al
    Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis.
    BMC Cancer. 2017;17:845.
    PubMed     Text format     Abstract available


  35. CAO GD, Chen K, Chen B, Xiong MM, et al
    Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
    BMC Cancer. 2017;17:841.
    PubMed     Text format     Abstract available


  36. KAWAMOTO Y, Komatsu Y, Yuki S, Sawada K, et al
    Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    BMC Cancer. 2017;17:837.
    PubMed     Text format     Abstract available


    November 2017
  37. GHOSH S, Bankura B, Ghosh S, Saha ML, et al
    Polymorphisms in ADH1B and ALDH2 genes associated with the increased risk of gastric cancer in West Bengal, India.
    BMC Cancer. 2017;17:782.
    PubMed     Text format     Abstract available


  38. RYU BK, Lee MG, Kim NH, Lee KY, et al
    Bidirectional alteration of Cav-1 expression is associated with mitogenic conversion of its function in gastric tumor progression.
    BMC Cancer. 2017;17:766.
    PubMed     Text format     Abstract available


  39. HAMASHIMA C, Narisawa R, Ogoshi K, Kato T, et al
    Optimal interval of endoscopic screening based on stage distributions of detected gastric cancers.
    BMC Cancer. 2017;17:740.
    PubMed     Text format     Abstract available


  40. FENG F, Tian Y, Xu G, Liu Z, et al
    Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
    BMC Cancer. 2017;17:737.
    PubMed     Text format     Abstract available


    October 2017
  41. LEE HH, Lee SH, Song KY, Na SJ, et al
    Evaluation of Slug expression is useful for predicting lymph node metastasis and survival in patients with gastric cancer.
    BMC Cancer. 2017;17:670.
    PubMed     Text format     Abstract available


  42. SANCHEZ-ZAUCO N, Torres J, Gomez A, Camorlinga-Ponce M, et al
    Correction to: Circulating blood levels of IL-6, IFN-gamma, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study.
    BMC Cancer. 2017;17:669.
    PubMed     Text format    


  43. LIU S, Zhang Y, Chen L, Guan W, et al
    Whole-lesion apparent diffusion coefficient histogram analysis: significance in T and N staging of gastric cancers.
    BMC Cancer. 2017;17:665.
    PubMed     Text format     Abstract available


    September 2017
  44. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Text format     Abstract available


  45. YE J, Huang J, Xu J, Huang Q, et al
    ERp29 controls invasion and metastasis of gastric carcinoma by inhibition of epithelial-mesenchymal transition via PI3K/Aktsignaling pathway.
    BMC Cancer. 2017;17:626.
    PubMed     Text format     Abstract available


    August 2017
  46. PARK SM, Lee J, Kim YA, Chang YJ, et al
    Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea.
    BMC Cancer. 2017;17:600.
    PubMed     Text format     Abstract available


  47. JI X, Bu ZD, Li ZY, Wu AW, et al
    Prognostic significance of the total number of harvested lymph nodes for lymph node-negative gastric cancer patients.
    BMC Cancer. 2017;17:558.
    PubMed     Text format     Abstract available


  48. LEE YH, Lee JW, Jang HS
    Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer.
    BMC Cancer. 2017;17:541.
    PubMed     Text format     Abstract available


    July 2017
  49. HAAG GM, Stocker G, Quidde J, Jaeger D, et al
    Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study.
    BMC Cancer. 2017;17:509.
    PubMed     Text format     Abstract available


    June 2017
  50. YOSHIZAWA J, Kubo N, Ishizone S, Karasawa F, et al
    Curative resection by splenectomy for solitary splenic metastasis from early gastric cancer: a case report and literature review.
    BMC Cancer. 2017;17:436.
    PubMed     Text format     Abstract available


    May 2017
  51. SANCHEZ-ZAUCO N, Torres J, Gomez A, Camorlinga-Ponce M, et al
    Circulating blood levels of IL-6, IFN-gamma, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study.
    BMC Cancer. 2017;17:384.
    PubMed     Text format     Abstract available


  52. CHANG YW, Oh CH, Kim JW, Lee JW, et al
    Combination of Helicobacter pylori infection and the interleukin 8 -251 T > A polymorphism, but not the mannose-binding lectin 2 codon 54 G > A polymorphism, might be a risk factor of gastric cancer.
    BMC Cancer. 2017;17:388.
    PubMed     Text format     Abstract available


  53. YOSHIZAWA J, Ishizone S, Ikeyama M, Nakayama J, et al
    Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature.
    BMC Cancer. 2017;17:368.
    PubMed     Text format     Abstract available


  54. JI X, Yan Y, Bu ZD, Li ZY, et al
    The optimal extent of gastrectomy for middle-third gastric cancer: distal subtotal gastrectomy is superior to total gastrectomy in short-term effect without sacrificing long-term survival.
    BMC Cancer. 2017;17:345.
    PubMed     Text format     Abstract available


    April 2017
  55. SAITO H, Fushida S, Miyashita T, Oyama K, et al
    Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.
    BMC Cancer. 2017;17:294.
    PubMed     Text format     Abstract available


  56. SHIN HB, An JY, Lee SH, Choi YY, et al
    Is adjuvant chemotherapy necessary in pT1N1 gastric cancer?
    BMC Cancer. 2017;17:287.
    PubMed     Text format     Abstract available


  57. KIM GM, Kim SJ, Song SK, Kim HR, et al
    Prevalence and prognostic implications of psychological distress in patients with gastric cancer.
    BMC Cancer. 2017;17:283.
    PubMed     Text format     Abstract available


  58. WU Z, Zhao J, Gao P, Song Y, et al
    Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis.
    BMC Cancer. 2017;17:275.
    PubMed     Text format     Abstract available


  59. XING X, Cai W, Ma S, Wang Y, et al
    Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.
    BMC Cancer. 2017;17:268.
    PubMed     Text format     Abstract available


    March 2017
  60. SHU P, Qin J, Shen K, Chen W, et al
    The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III.
    BMC Cancer. 2017;17:238.
    PubMed     Text format     Abstract available


  61. WANG H, Lu J, Tang J, Chen S, et al
    Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    BMC Cancer. 2017;17:191.
    PubMed     Text format     Abstract available


  62. LIU X, Guo W, Zhang W, Yin J, et al
    A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
    BMC Cancer. 2017;17:188.
    PubMed     Text format     Abstract available


  63. LEE JW, Choi MH, Lee YJ, Ali B, et al
    Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection.
    BMC Cancer. 2017;17:185.
    PubMed     Text format     Abstract available


  64. HAMASHIMA C, Sasazuki S, Inoue M, Tsugane S, et al
    Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.
    BMC Cancer. 2017;17:183.
    PubMed     Text format     Abstract available


    February 2017
  65. LUO Y, Chen J, Huang K, Lin Y, et al
    Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
    BMC Cancer. 2017;17:154.
    PubMed     Text format     Abstract available


  66. CHEN Z, Liang W
    Myopericytoma occurrence in the liver and stomach space: imaging performance.
    BMC Cancer. 2017;17:143.
    PubMed     Text format     Abstract available


  67. KOMAKI K, Kusaba T, Tanaka M, Kado H, et al
    Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    BMC Cancer. 2017;17:144.
    PubMed     Text format     Abstract available


  68. LOZANO-POPE I, Sharma A, Matthias M, Doran KS, et al
    Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of Helicobacter-induced gastric cancer.
    BMC Cancer. 2017;17:133.
    PubMed     Text format     Abstract available


  69. YU B, Chen X, Li J, Gu Q, et al
    microRNA-29c inhibits cell proliferation by targeting NASP in human gastric cancer.
    BMC Cancer. 2017;17:109.
    PubMed     Text format     Abstract available


    January 2017
  70. HUR H, Ham IH, Lee D, Jin H, et al
    Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma.
    BMC Cancer. 2017;17:87.
    PubMed     Text format     Abstract available


  71. RAO SV, Solum G, Niederdorfer B, Norsett KG, et al
    Gastrin activates autophagy and increases migration and survival of gastric adenocarcinoma cells.
    BMC Cancer. 2017;17:68.
    PubMed     Text format     Abstract available


  72. DIAO D, Cheng Y, Song Y, Zhang H, et al
    D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer.
    BMC Cancer. 2017;17:56.
    PubMed     Text format     Abstract available


  73. LEE NK, Lee JH, Ivan C, Ling H, et al
    MALAT1 promoted invasiveness of gastric adenocarcinoma.
    BMC Cancer. 2017;17:46.
    PubMed     Text format     Abstract available


  74. OKAZAKI M, Fushida S, Harada S, Tsukada T, et al
    Establishing a xenograft mouse model of peritoneal dissemination of gastric cancer with organ invasion and fibrosis.
    BMC Cancer. 2017;17:23.
    PubMed     Text format     Abstract available


  75. SONG H, Fang F, Valdimarsdottir U, Lu D, et al
    Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study.
    BMC Cancer. 2017;17:2.
    PubMed     Text format     Abstract available


    December 2016
  76. PU WY, Zhang R, Xiao L, Wu YY, et al
    Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA.
    BMC Cancer. 2016;16:943.
    PubMed     Text format     Abstract available


  77. HOFHEINZ R, Clouth J, Borchardt-Wagner J, Wagner U, et al
    Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
    BMC Cancer. 2016;16:937.
    PubMed     Text format     Abstract available


    November 2016
  78. SEO SH, Kim SE, Kang YK, Ryoo BY, et al
    Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients.
    BMC Cancer. 2016;16:900.
    PubMed     Text format     Abstract available


    October 2016
  79. FENG M, Yao G, Yu H, Qing Y, et al
    Tumor apelin, not serum apelin, is associated with the clinical features and prognosis of gastric cancer.
    BMC Cancer. 2016;16:794.
    PubMed     Text format     Abstract available


  80. JI X, Fu T, Bu ZD, Zhang J, et al
    Comparison of different methods of splenic hilar lymph node dissection for advanced upper- and/or middle-third gastric cancer.
    BMC Cancer. 2016;16:765.
    PubMed     Text format     Abstract available


    January 2016
  81. KUPCINSKAITE-NOREIKIENE R, Ugenskiene R, Noreika A, Rudzianskas V, et al
    Gene methylation profile of gastric cancerous tissue according to tumor site in the stomach.
    BMC Cancer. 2016;16:40.
    PubMed     Text format     Abstract available


  82. LI SX, Seo SH, Choi YY, Nakagawa M, et al
    Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy.
    BMC Cancer. 2016;16:29.
    PubMed     Text format     Abstract available


  83. ITO K, Mitsunaga M, Arihiro S, Saruta M, et al
    Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms.
    BMC Cancer. 2016;16:37.
    PubMed     Text format     Abstract available


  84. PARK CH, Cho SY, Ha JD, Jung H, et al
    Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.
    BMC Cancer. 2016;16:35.
    PubMed     Text format     Abstract available


  85. CHANG HR, Park HS, Ahn YZ, Nam S, et al
    Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
    BMC Cancer. 2016;16:200.
    PubMed     Text format     Abstract available


  86. EFTANG LL, Klajic J, Kristensen VN, Tost J, et al
    GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer.
    BMC Cancer. 2016;16:225.
    PubMed     Text format     Abstract available


  87. LIU N, Zhou N, Chai N, Liu X, et al
    Helicobacter pylori promotes angiogenesis depending on Wnt/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer.
    BMC Cancer. 2016;16:321.
    PubMed     Text format     Abstract available


  88. PARK JY, Kim YW, Ryu KW, Nam BH, et al
    Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer-A multicenter randomized phase III clinical trial (SENORITA trial) protocol.
    BMC Cancer. 2016;16:340.
    PubMed     Text format     Abstract available


  89. HARADA K, Baba Y, Shigaki H, Ishimoto T, et al
    Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review.
    BMC Cancer. 2016;16:400.
    PubMed     Text format     Abstract available


  90. LIM SM, Kim YN, Park KH, Kang B, et al
    Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients.
    BMC Cancer. 2016;16:385.
    PubMed     Text format     Abstract available


  91. WANG H, Zhang H, Deng P, Liu C, et al
    Tissue metabolic profiling of human gastric cancer assessed by (1)H NMR.
    BMC Cancer. 2016;16:371.
    PubMed     Text format     Abstract available


  92. YU X, Hu F, Yao Q, Li C, et al
    Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study.
    BMC Cancer. 2016;16:480.
    PubMed     Text format     Abstract available


  93. LIU S, Feng F, Xu G, Liu Z, et al
    Clinicopathological features and prognosis of gastric cancer in young patients.
    BMC Cancer. 2016;16:478.
    PubMed     Text format     Abstract available


  94. GUO H, Xia B
    Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer.
    BMC Cancer. 2016;16:565.
    PubMed     Text format     Abstract available


  95. ZHAO JH, Gao P, Song YX, Sun JX, et al
    Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis.
    BMC Cancer. 2016;16:631.
    PubMed     Text format     Abstract available


  96. LICHTHARDT S, Kerscher A, Dietz UA, Jurowich C, et al
    Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer.
    BMC Cancer. 2016;16:650.
    PubMed     Text format     Abstract available


  97. WANG T, Fei HJ, Yang Y, Jiang XS, et al
    Expression of AE1/p16 promoted degradation of AE2 in gastric cancer cells.
    BMC Cancer. 2016;16:716.
    PubMed     Text format     Abstract available


  98. ZOU K, Yang S, Zheng L, Yang C, et al
    Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review.
    BMC Cancer. 2016;16:737.
    PubMed     Text format     Abstract available


  99. PARK WC, Kim HR, Kang DB, Ryu JS, et al
    Comparative expression patterns and diagnostic efficacies of SR splicing factors and HNRNPA1 in gastric and colorectal cancer.
    BMC Cancer. 2016;16:358.
    PubMed     Text format     Abstract available


    January 2015
  100. HE X, Li B, Shao Y, Zhao N, et al
    Cell fusion between gastric epithelial cells and mesenchymal stem cells results in epithelial-to-mesenchymal transition and malignant transformation.
    BMC Cancer. 2015;15:24.
    PubMed     Text format     Abstract available


  101. SAEKI N, Komatsuzaki R, Chiwaki F, Yanagihara K, et al
    A GSDMB enhancer-driven HSV thymidine kinase-expressing vector for controlling occult peritoneal dissemination of gastric cancer cells.
    BMC Cancer. 2015;15:439.
    PubMed     Text format     Abstract available


  102. HO AL, Szulakowsi P, Mohamid WH
    The diagnostic challenge of pulmonary tumour thrombotic microangiopathy as a presentation for metastatic gastric cancer: a case report and review of the literature.
    BMC Cancer. 2015;15:450.
    PubMed     Text format     Abstract available


  103. PAK KH, Jo A, Choi HJ, Choi Y, et al
    The different role of intratumoral and peritumoral lymphangiogenesis in gastric cancer progression and prognosis.
    BMC Cancer. 2015;15:498.
    PubMed     Text format     Abstract available


  104. LEONG T, Smithers BM, Michael M, Gebski V, et al
    TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    BMC Cancer. 2015;15:532.
    PubMed     Text format     Abstract available


  105. ROCHA GA, Rocha AM, Gomes AD, Faria CL Jr, et al
    STAT3 polymorphism and Helicobacter pylori CagA strains with higher number of EPIYA-C segments independently increase the risk of gastric cancer.
    BMC Cancer. 2015;15:528.
    PubMed     Text format     Abstract available


  106. HAVERKAMP L, Brenkman HJ, Seesing MF, Gisbertz SS, et al
    Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial).
    BMC Cancer. 2015;15:556.
    PubMed     Text format     Abstract available


  107. SUBHASH VV, Tan SH, Tan WL, Yeo MS, et al
    GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.
    BMC Cancer. 2015;15:550.
    PubMed     Text format     Abstract available


  108. HO AL, Szulakowski P, Mohamid WH
    Erratum to: The diagnostic challenge of pulmonary tumour thrombotic microangiopathy as a presentation for metastatic gastric cancer: A case report and review of the literature.
    BMC Cancer. 2015;15:600.
    PubMed     Text format    


  109. LI D, Zhang J, Xi Y, Zhang L, et al
    Mitogen-activated protein kinase activator with WD40 repeats (MAWD) and MAWD-binding protein induce cell differentiation in gastric cancer.
    BMC Cancer. 2015;15:637.
    PubMed     Text format     Abstract available


  110. HE J, Shi H, Zhou Z, Chen J, et al
    Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study.
    BMC Cancer. 2015;15:749.
    PubMed     Text format     Abstract available


  111. LI L, Gan Y, Wu C, Qu X, et al
    Coffee consumption and the risk of gastric cancer: a meta-analysis of prospective cohort studies.
    BMC Cancer. 2015;15:733.
    PubMed     Text format     Abstract available


  112. TAKAHASHI H, Kaniwa N, Saito Y, Sai K, et al
    Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method.
    BMC Cancer. 2015;15:718.
    PubMed     Text format     Abstract available


  113. BOCCARDI V, Marano L, Rossetti RR, Rizzo MR, et al
    Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker.
    BMC Cancer. 2015;15:703.
    PubMed     Text format     Abstract available


  114. XUE J, Zhu Y, Sun Z, Ji R, et al
    Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness.
    BMC Cancer. 2015;15:793.
    PubMed     Text format     Abstract available


  115. LIU X, Liu J, Qiu H, Kong P, et al
    Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis.
    BMC Cancer. 2015;15:782.
    PubMed     Text format     Abstract available


  116. WANG Z, Liu H, Shen Z, Wang X, et al
    The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients.
    BMC Cancer. 2015;15:766.
    PubMed     Text format     Abstract available


  117. ZHU Y, Tian T, Zou J, Wang Q, et al
    Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    BMC Cancer. 2015;15:894.
    PubMed     Text format     Abstract available


  118. LIU Z, Guo J, Wang S, Zhao Y, et al
    Evaluation of transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent for gastric cancer.
    BMC Cancer. 2015;15:932.
    PubMed     Text format     Abstract available


  119. YOLANDA LV, Sergio PD, Hugo ES, Isabel AF, et al
    Gastric cancer progression associated with local humoral immune responses.
    BMC Cancer. 2015;15:924.
    PubMed     Text format     Abstract available


  120. NAKAGAWA M, Choi YY, An JY, Chung H, et al
    Difficulty of predicting the presence of lymph node metastases in patients with clinical early stage gastric cancer: a case control study.
    BMC Cancer. 2015;15:943.
    PubMed     Text format     Abstract available


  121. SU HJ, Zhang Y, Zhang L, Ma JL, et al
    Methylation status of COX-2 in blood leukocyte DNA and risk of gastric cancer in a high-risk Chinese population.
    BMC Cancer. 2015;15:979.
    PubMed     Text format     Abstract available


  122. LI XW, Shi BY, Yang QL, Wu J, et al
    Epigenetic regulation of CDH1 exon 8 alternative splicing in gastric cancer.
    BMC Cancer. 2015;15:954.
    PubMed     Text format     Abstract available


  123. LEE JW, Ali B, Yoo HM, Park CH, et al
    Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy.
    BMC Cancer. 2015;15:1005.
    PubMed     Text format     Abstract available


  124. SEYFRIED F, von Rahden BH, Miras AD, Gasser M, et al
    Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients.
    BMC Cancer. 2015;15:73.
    PubMed     Text format     Abstract available


  125. FU T, Bu ZD, Li ZY, Zhang LH, et al
    Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials.
    BMC Cancer. 2015;15:322.
    PubMed     Text format     Abstract available


  126. LI K, Du H, Lian X, Chai D, et al
    Establishment and characterization of a metastasis model of human gastric cancer in nude mice.
    BMC Cancer. 2016;16:54.
    PubMed     Text format     Abstract available


  127. PAK KH, Kim DH, Kim H, Lee do H, et al
    Differences in TGF-beta1 signaling and clinicopathologic characteristics of histologic subtypes of gastric cancer.
    BMC Cancer. 2016;16:60.
    PubMed     Text format     Abstract available


  128. DORES GM, Qubaiah O, Mody A, Ghabach B, et al
    A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010.
    BMC Cancer. 2015;15:185.
    PubMed     Text format     Abstract available


  129. GONG J, Liu T, Fan Q, Bai L, et al
    Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
    BMC Cancer. 2016;16:68.
    PubMed     Text format     Abstract available


  130. SATO Y, Kubo T, Morimoto K, Yanagihara K, et al
    High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells.
    BMC Cancer. 2016;16:63.
    PubMed     Text format     Abstract available


  131. PAK KH, Kim DH, Kim H, Lee do H, et al
    Erratum to: Differences in TGF-beta1 signaling and clinicopathologic characteristics of histologic subtypes of gastric cancer.
    BMC Cancer. 2016;16:99.
    PubMed     Text format    


  132. CARDOSO AP, Pinto ML, Pinto AT, Pinto MT, et al
    Matrix metalloproteases as maestros for the dual role of LPS- and IL-10-stimulated macrophages in cancer cell behaviour.
    BMC Cancer. 2015;15:456.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: